EHA 2017 | Are biosimilars as efficacious as their reference drugs?
Paul Cornes, MD, from the University Hospital Bristol NHS Foundation Trust, Bristol, UK, talks to us about biosimilars and whether they are suitable as a cheaper alternative to current reference drugs. He explains the concern with biosimilars, namely in their switching over from reference drugs in cancer treatment, due to the possibility of them possessing different antibody profiles. This interview was filmed at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.
Get great new content delivered to your inboxSign up